Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Newer GLP-1 receptor agonists and obesity-diabetes.

Literature DB >> 29412833

Newer GLP-1 receptor agonists and obesity-diabetes.

Emily Brown¹, Daniel J Cuthbertson¹, John P Wilding².

Abstract

Obesity is a major risk factor for type 2 diabetes and may complicate type 1 diabetes. In parallel with the global epidemic of obesity, the incidence of type 2 diabetes is increasing exponentially. To reverse these alarming trends, weight loss becomes a major therapeutic priority in prevention and treatment of type 2 diabetes. Given that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve glycaemic control and cause weight loss, they are receiving increasing attention for the treatment of diabetes-obesity. This review discusses current and emerging therapeutic options with GLP-1 RAs and considers the next generation of novel peptide co-agonists with the potential for improved therapeutic outcomes in obesity and type 2 diabetes.

Entities: Disease Gene

Keywords: Diabetes; GLP-1 agonists; Obesity; Review

Mesh：

Substances：

Year: 2018 PMID： 29412833 DOI： 10.1016/j.peptides.2017.12.009

Source DB: PubMed Journal: Peptides ISSN： 0196-9781 Impact factor: 3.750

Keyword Cloud
Cited

15 in total

Review 1. Membranes under the Magnetic Lens: A Dive into the Diverse World of Membrane Protein Structures Using Cryo-EM.

Authors: Sarah J Piper; Rachel M Johnson; Denise Wootten; Patrick M Sexton
Journal: Chem Rev Date: 2022-07-18 Impact factor: 72.087

Review 2. Signaling pathways in obesity: mechanisms and therapeutic interventions.

Authors: Xue Wen; Bohan Zhang; Beiyi Wu; Haitao Xiao; Zehua Li; Ruoyu Li; Xuewen Xu; Tao Li
Journal: Signal Transduct Target Ther Date: 2022-08-28

3. Long-term functional alterations following prenatal GLP-1R activation.

Authors: Devon L Graham; Haley S Madkour; Brenda L Noble; Chris Schatschneider; Gregg D Stanwood
Journal: Neurotoxicol Teratol Date: 2021-04-20 Impact factor: 4.071

4. GLP-1R activation alters performance in cognitive tasks in a sex-dependent manner.

Authors: Taylor S Trammell; Natalie L Henderson; Haley S Madkour; Gregg D Stanwood; Devon L Graham
Journal: Neurol Sci Date: 2020-11-22 Impact factor: 3.830

5. A glycosylated Fc-fused glucagon-like peptide-1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide.

Authors: In Bok An; Mi Sun Byun; Sang In Yang; Yuri Choi; Jung Won Woo; Hak Chul Jang; Young Chul Sung
Journal: Diabetes Obes Metab Date: 2020-06-03 Impact factor: 6.577

Newer GLP-1 receptor agonists and obesity-diabetes.

Review 1. Membranes under the Magnetic Lens: A Dive into the Diverse World of Membrane Protein Structures Using Cryo-EM.

Review 2. Signaling pathways in obesity: mechanisms and therapeutic interventions.

3. Long-term functional alterations following prenatal GLP-1R activation.

4. GLP-1R activation alters performance in cognitive tasks in a sex-dependent manner.

5. A glycosylated Fc-fused glucagon-like peptide-1 receptor agonist exhibits equivalent glucose lowering to but fewer gastrointestinal side effects than dulaglutide.

6. Liraglutide and Insulin Have Contrary Effects on Adipogenesis of Human Adipose-Derived Stem Cells via Wnt Pathway.

Review 7. Incretin Hormones in Obesity and Related Cardiometabolic Disorders: The Clinical Perspective.

Review 8. Irisin and Incretin Hormones: Similarities, Differences, and Implications in Type 2 Diabetes and Obesity.

Review 9. Proglucagon-Derived Peptides as Therapeutics.

Review 10. A 2021 Update on the Use of Liraglutide in the Modern Treatment of 'Diabesity': A Narrative Review.